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In randomized trials of provider-focused clinical interventions, treatment allocation often cannot be blinded to par-
ticipants, study staff, or providers. The choice of unit of randomization (patient, provider, or clinic) entails tradeoffs in
cost, power, and bias. Provider- or clinic-level randomization can minimize contamination, but it incurs the equally
problematic potential for referral bias; that is, because arm assignment of future participants generally cannot be
concealed, differences between armsmay arise in the types of patients enrolled. Pseudo-cluster randomization is a
novel study design that balances these competing validity threats. Providers are randomly assigned to an imbal-
anced proportion of intervention-arm participants (e.g., 80% or 20%). Providers can be masked to the imbalance,
avoiding referral bias. Contamination is reduced because only a minority of control-arm participants are treated by
majority-intervention providers. Pseudo-cluster randomization was implemented in a randomized trial of a decision
support intervention to manage depression among patients receiving human immunodeficiency virus care in the
southern United States in 2010–2014. The design appears successful in avoiding referral bias (participants
were comparable between arms on important characteristics) and contamination (key depression treatment indica-
tors were comparable between usual care participants managed by majority-intervention and majority-usual care
providers and were markedly different compared with intervention participants).
clinical trials; contamination; pseudo-cluster randomization; referral bias; study design
Abbreviations: HIV, human immunodeficiency virus; SLAM DUNC, Strategies to Link Antiretroviral and Antidepressant Management
at Duke, University of Alabama-Birmingham, Northern Outreach Clinic, and the University of North Carolina at Chapel Hill.
For the highly valued randomized controlled trial study de-
sign, the validity of conclusions is dependent on at least 2
critical conditions. First, randomizationmust be implemented
impartially, especially independent of knowledge of treat-
ment arm, so that selection bias does not undermine the com-
parability of the treatment arms. Second, contamination must
be minimized, so that participants actually receive the condi-
tion towhich theywere assigned and, in particular, those in the
comparison arm do not receive the active intervention.
In considering these 2 conditions, researchers frequently
face competing concerns in selecting the optimal unit of ran-
domization in trials of health service delivery interventions.
Although medication trials can use double-blinded, placebo-
controlled designs to ensure that recruitment and patient and
provider behavior are unaffected by knowledge of treatment
arm, such blinding is often not possible for service delivery
interventions. For example, if a trial focused on improving
depression seeks to compare usual care with care by a depres-
sion “care manager” who guides the provider in prescribing
and dosing antidepressants, neither the participant, provider,
nor depression care manager can be blinded to treatment arm.
If such a study were to implement patient-level randomiza-
tion, with providers caring for both intervention and usual
care participants, contamination would be a concern: Provid-
ers might apply principles from the depression care manager
to improve their treatment of usual care participants. This con-
tamination would tend to improve outcomes in the usual care
arm, reducing the observed effect size and the trial’s power
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(1, 2). To avoid contamination, the trial might elect provider-
or clinic-level (cluster) randomization, so that all patients of a
given provider or clinic would be in 1 arm.
While addressing contamination, cluster randomization
may incur a competing threat of selection or referral bias, be-
cause the treatment arm assignment of future enrollees cannot
be masked from providers or staff (at least after the assign-
ment of that provider’s first participant is revealed). Unless
a study’s accrual can be completed before any treatment arm
assignments are made, treatment arm will already be known
for most participants before they are approached for enroll-
ment. This foreknowledge may guide providers or staff, con-
sciously or subconsciously, to recruit with different vigor or
to enroll different types of patients in the arms, erasing the cri-
tical conditionof comparability betweenarmsonwhich causal
inference depends (3, 4). For example, a cluster-randomized
trial of a comparison of a new palliative care intervention with
conventional care found, after the fact, that different types of
patients had been enrolled into the 2 arms because of the
clinical staff’s awareness of arm assignment (5). Similarly,
systematic reviews of hip protector trials have found that in-
dividually randomized trials have had mixed results, while
cluster-randomized trials have consistently shown substantial
benefits of hip protectors, likely due to preferential selection
of patients into the intervention arms who were most likely to
benefit (6, 7). Cluster randomization is also less efficient (re-
quires a larger sample size) than individual randomization
because of the design effect or the dependence of outcomes
for participants within a cluster (1, 8).
Pseudo-cluster randomization is a novel study design de-
veloped to balance these competing threats of contamina-
tion and referral bias (9). Originally developed for the Dutch
EASYCare Study, a trial of a new primary care management
strategy for older adults compared with usual care, the design
uses random assignment of providers to an imbalanced case
mix (e.g., 80% intervention/20% usual care or 20% interven-
tion/80% usual care). Contamination is reduced, although not
eliminated, because most usual care arm participants are
cared for by a provider with minimal exposure to the inter-
vention. Referral bias is reduced because all participants have
a nonzero probability of assignment to either arm and can be
further avoided by masking providers and study staff to the
use of imbalanced randomization. Pseudo-cluster random-
ization also improves efficiency relative to classic cluster
randomization. Here, we describe the rationale for and imple-
mentation of pseudo-cluster randomization in a randomized
trial of a depression care management strategy, compared
with usual care, among patients with depression engaged in
human immunodeficiency virus (HIV) care, known as the
Strategies to Link Antiretroviral and Antidepressant Manage-
ment at Duke, University of Alabama-Birmingham, Northern
Outreach Clinic, and the University of North Carolina at
Chapel Hill (SLAM DUNC) Study.
METHODS
The SLAM DUNC Study
This study is a 4-site randomized trial of the effect of de-
pression treatment on antiretroviral medication adherence
among HIV-infected patients with major depression (10).
Participants in the intervention arm received Measurement-
Based Care. Measurement-Based Care involves management
by a depression care manager who uses regular assessments
of key depression treatmentmetrics (depressive severity,med-
ication adherence, medication side effects) and an evidence-
based decision algorithm to recommend treatment changes to
the treating HIVmedical provider (11). For participants in the
usual care arm, the treating HIV medical provider was free to
refer or implement any depression treatment plan but did not
receive support from the depression care manager.
In designing the study, we recognized limitations with
both patient-level and provider-level randomization. Patient-
level randomization raised the potential for contamination as
described earlier. For this reason, the study was originally de-
signed and funded with a provider-randomized design. How-
ever, in the protocol development phase, the study team
became concerned about the potential for referral bias. This
potential would arise because randomization could not be de-
layed until study accrual was complete, given the expected
pace of recruitment and the desire not to delay initiation of
treatment of the presenting depressive episode, and providers
would therefore be aware of their arm assignment during
recruitment. Providers were expected to have a strong prefer-
ence for the intervention over usual care. As a result, with
funder approval, the study team changed the design to pseudo-
cluster randomization.
Pseudo-cluster randomization
In the Dutch EASYCare Study, Teerenstra et al. (9) de-
veloped a novel modification of the traditional provider-
randomized design, called pseudo-cluster randomization, to
balance contamination and referral bias. In pseudo-cluster
randomization, each provider is randomly assigned not to
an arm but to a specific majority/minority case mix. In the
Dutch EASYCare Study, for example, each provider was ran-
domly assigned to either an 80% intervention/20% usual care
case mix or a 20% intervention/80% usual care case mix.
Each presenting patient was randomly assigned upon recruit-
ment, with assignment probabilities defined by the provider’s
case mix assignment. The potential for referral bias is reduced
because each patient has a nonzero probability of receiving
the intervention. Further, the case mix proportions—or even
the use of imbalanced proportions—can be masked, and if the
number of patients per provider is small, it will be difficult for
the provider to suspect imbalanced randomization or to guess
their assignment. Yet the design also addresses contami-
nation. Usual care patients of majority-intervention arm pro-
viders may receive some components of the intervention
condition, but these patients represent only a small fraction
of all usual care patients. Usual care patients of majority-
usual care arm providers are unlikely to receive intervention
components because the exposure of the provider to the inter-
vention is minimal.
Pseudo-cluster randomized designs can be analyzed by
using the same statistical techniques as cluster-randomized
designs, although alternatives have also been proposed (12).
Efficiency is improved relative to a classic cluster-randomized
design because the design effect is reduced (9). For a classic
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cluster-randomized design, sample size is the product of the
required sample size with an individually randomized study
multiplied by the design effect, D = 1 + (n− 1)ρ (8), where n
is the mean cluster size and ρ is the intracluster correlation co-
efficient. In a pseudo-cluster randomized study, the design ef-
fect, Dpc, depends additionally on f, the case-mix proportion
within clusters: Dpc = [1 + (n− 1)ρ]/[1 + 4f(1− f )nρ/(1− ρ)].
In most cases, Dpc is substantially smaller than D (9). These
formulas assume balanced cluster sizes; in the presence of un-
balanced cluster sizes, power is likely to be reduced (13).
Sample size determination
The SLAM DUNC Study power calculations were de-
signed to detect a 10 percentage point improvement in anti-
retroviral medication adherence, measured as a continuous
variable, at 6 months after randomization. Previous studies
suggested that the outcome would have a pooled standard de-
viation of between 25% and 29% (14), implying a Cohen’s
effect size of 0.345–0.400. For individual-level randomi-
zation, with 2-tailed 5% type I error probability and 80%
power, the required sample size was 268 (134 per arm) for
the smaller (conservative) effect size of 0.345. For classic
provider-level randomization, the design effect was calcu-
lated as D = 1.16, based on estimates of 9 patients per pro-
vider and ρ = 0.02 (15–18). Thus, the required combined
sample size for a classic provider randomized design would
be 268 × 1.16 = 312. This number, increased to 390 in antic-
ipation of 20% loss to follow-up at 6 months, was the origi-
nally funded sample size.
In implementing pseudo-cluster randomization, the study
team selected a case-mix proportion ( f ) of 0.8, selected to
balance contamination against the risk of unmasking the un-
balanced design to providers and staff. This choice reduced
the design effect to Dpc = 1.04. However, it was recognized
that some contamination might occur, even though contami-
nation would be reduced relative to patient-level randomiza-
tion. Given that contamination would require substantial
effort on providers’ part (to replicate the depression care
manager’s schedule of regular systematic assessments) and
that only 20% of usual care participants would be exposed
to majority-intervention arm providers, the study team antic-
ipated that a reduction in the effect size of 5%–10% due to
contamination was realistic. This implied an effect size of
0.310–0.380 depending on the amount of contamination
(5%–10%) and pooled standard deviation (25%–29%). The
originally funded sample of 312 (corresponding to 300 in
an individual design multiplied by Dpc = 1.04) therefore pro-
vided ≥80% power for most scenarios (effect size ≥ 0.328)
and 76% power for the worst-case scenario (effect size =
0.310, corresponding to 10% contamination and pooled
standard deviation of 29%). Given funding constraints, the
originally funded sample size was therefore maintained.
Randomization
Providers were randomized 1:1 to either a majority (80%)
intervention or majority usual care case mix. Randomization
was stratified by site (3 levels; the smallest site was combined
with another site because of shared providers) and by ex-
perience and comfort with antidepressant management (di-
vided into high/moderate/low tertiles), as it was anticipated
that provider experience and comfort would affect treatment
quality and therefore participant treatment response, especially
in the usual care arm. Experience and comfort with antidepres-
sant management were assessed via a semistructured baseline
provider interview assessing providers’ standard practice in
identifying depression and initiating andmanaging antidepres-
sant treatment (19). Provider randomization was implemented
in blocks of 4 within each site/experience stratum. For the
purposes of randomization, Infectious Diseases fellows who
managed patients in consultation with an attending physician
were considered 1 unit with their attending physician.
Once providers were assigned to case mixes, randomiza-
tion sequences for each provider’s patients were determined
in blocks of 10. For example, a majority intervention provider
would have a sequence with 8 intervention arm slots and 2
usual care arm slots, in random order. Randomization se-
quences were generated and maintained by the study statisti-
cian and were available only to limited study staff who were
not involved in recruitment activities. When a new partici-
pant enrolled in the study, recruitment staff would call the co-
ordinating center, report certain information including the
participant’s provider, and would be given the participant’s
arm assignment. At 1 site, each patient was managed by a
team of an attending physician and a mid-level provider or
fellow; participants at this site were randomized on the basis
of the case mix of their team’s attending physician. Regular
quality assurancewas conducted to ensure that slots were cor-
rectly assigned in the specified order.
Blinding and ethical considerations
In the institutional review board protocol, the study team
indicated the intention to use pseudo-cluster randomization
but to blind participants, providers, and nearly all study staff
to the pseudo-cluster aspect of the design. Blinding to the de-
sign was perceived as necessary to avoid referral bias. Blind-
ing was further expected to pose negligible risk of harm to
participants or providers because all enrolling participants
would have a nonzero probability of being assigned to either
arm. The principal investigator and co-principal investigator,
a small number of senior clinical investigators, and study staff
handling institutional review board correspondence were the
only ones informed of the pseudo-cluster aspect of the de-
sign. Patient and provider consent forms both stated that pa-
tients would be “randomly assigned” to 1 of 2 arms. The study
team planned to disclose the pseudo-cluster design to partic-
ipating providers after the conclusion of the study.
Analysis
The study’s Statistical Analysis Plan prespecified that
analyses would be intention to treat and would address the
pseudo-cluster randomized design. The intervention effect
is estimated as the difference between arms in the primary
(continuous) outcome at 6 months, estimated from a linear
mixed model fit to a data set with one 6-month observation
per participant, including an indicator variable for study
arm, fixed effects for stratification variables (site and provider
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experience with depression treatment), and random effects
for providers (to address clustering by provider).
To assess the effectiveness of the implementation of the
pseudo-cluster randomization, we compared the characteris-
tics of the 2 groups of providers and the observed distribution
of number of patients in each arm per provider. To evaluate
whether referral bias occurred, we compared the characteris-
tics of the participants randomized to each arm.
To assess the extent of contamination in the usual care arm,
we compared key indicators of the depression treatment ap-
proach (i.e., use of intervention components) between usual
care arm participants being treated by majority-usual care
arm providers, usual care arm participants being treated by
majority-intervention arm providers, and intervention arm
participants (irrespective of provider assignment). Compari-
son of these 3 groups allows us to distinguish between 3 com-
peting hypotheses. If little contamination occurred with
either type of provider, we would expect usual care partici-
pants of both majority-usual care and majority-intervention
providers to have depression treatment indicators similar to
each other, but substantially worse indicators than interven-
tion participants (assuming that high fidelity was achieved in
the intervention arm). If contamination of usual care occurred
with the majority-intervention providers but was limited with
the majority-usual care providers (the goal of pseudo-cluster
randomization), we would expect usual care participants of
majority-usual care providers to have substantially worse in-
dicators than intervention participants, with indicators for
usual care participants of majority-intervention providers
falling in the middle. If substantial contamination of usual
care occurred with both types of providers, we would expect
similar depression treatment indicators in all 3 groups.
Accordingly, we present differences and 95% confidence
intervals comparing these indicators between 1) usual care
participants of majority-usual care providers versus all inter-
vention participants (expected to favor the intervention) and
2) usual care participants of majority-intervention providers
versus usual care participants of majority-usual care provid-
ers (in the absence of contamination, expected to be null; in
the presence of contamination, expected to favor usual care
participants of majority-intervention providers). Differences
and confidence intervals were estimated by using generalized
linear regression models with an identity link, binomial error
distribution, and clustering by provider. Fixed effects for de-
sign variables (site, depression treatment experience) yielded
convergence problems for the linear-binomial model, given
the small cells in some of these subgroup comparisons, and
were therefore excluded from these models.
The depression treatment indicators that we considered in-
cluded the presence and dosing level of an antidepressant at
Table 1. Characteristics of HIV Providers, SLAM DUNC Study, Southern United States, 2010–2014
Characteristic
Majority Intervention
Providers (n = 28)
Majority Usual Care
Providers (n = 25)
No. % Mean (SD) No. % Mean (SD)
Stratification factors
Site
1 and 4 11 39 9 36
2 9 32 8 32
3 8 29 8 32
Depression treatment practices score (range, 0–10) 5.3 (2.1) 5.5 2.5 5.5 (2.5)
High 9 32 10 40
Medium 9 32 8 32
Low 10 36 7 28
Other
Training
Attending physician 23 82 21 84
Mid-level providera 5 18 4 16
Clinical effort, % 38 (26) 37 (20)
% of clinical effort devoted to HIV 64 (34) 71 (28)
Years treating HIV 12.9 (7.4) 14.5 (9.4)
Confidence prescribing antidepressants (range, 1–5)b 3.2 (1.0) 3.7 (0.8)
Confidence changing antidepressants (range, 1–5)b 2.4 (0.8) 2.9 (0.9)
Believes treating depression is part of role (range, 1–5)b 3.9 (1.0) 3.9 (1.0)
Abbreviations: HIV, human immunodeficiency virus; SD, standard deviation; SLAM DUNC, Strategies to Link
Antidepressant and Antiretroviral Management at Duke, University of Alabama-Birmingham, Northern Outreach
Clinic, and the University of North Carolina at Chapel Hill.
a Nurse practitioner or physician assistant.
b On a1–5 scale, 1 = no confidence or belief, and 5 = strong confidence or belief.
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the time of enrollment (expected to be balanced) and the pres-
ence and dosing level of an antidepressant at 3 months after
enrollment (expected to favor the intervention arm). Anti-
depressant dosing levels were defined as low, moderate, or high
as defined previously on the basis of standard dosing guide-
lines (11, 20). Additional indicators included the proportion
Table 2. Actual Distribution of Participant Arm Assignments, by Provider Assignment, Among HIV Providers and HIV Patients With Depression,























24a 146 6.1 1–18 112 4.7 1–15 34 1.4 0–3
Majority usual care
providers
25 158 6.3 1–21 37 1.5 0–5 121 4.8 0–17
Abbreviations: HIV, human immunodeficiency virus; SLAM DUNC, Strategies to Link Antidepressant and Antiretroviral Management at Duke,
University of Alabama-Birmingham, Northern Outreach Clinic, and the University of North Carolina at Chapel Hill.
a Four providers randomized to majority intervention never enrolled any patients.
Table 3. Comparison of Baseline Characteristics of HIV Patients With Depression, SLAM DUNC Study, Southern
United States, 2010–2014
Characteristic
Intervention (n = 149) Usual Care (n = 155)
No. % Mean (SD) No. % Mean (SD)
Age, years 42.8 (10.3) 44.9 (9.9)
Present sex
Male 112 75.2 100 64.5
Female 35 23.5 52 33.5
Transgender and other 2 1.3 3 1.9
Sexual orientation
Heterosexual 58 39.7 81 53.3
Gay/lesbian 67 45.9 51 33.6
Bisexual 17 11.6 16 10.5
Other 4 2.7 4 2.6
Race/ethnicity
White non-Hispanic 54 36.2 39 25.2
Black non-Hispanic 83 55.7 105 67.7
Hispanic 9 6.0 4 2.6
Other 3 2.0 7 4.5
Employment status
Employed full time 22 15.0 22 14.4
Employed part time 17 11.6 20 13.1
Unemployed 108 73.5 111 72.5
SF-12 physical functioning score (range, 0–100) 44.1 (11.8) 43.8 (12.1)
SF-12 mental functioning score (range, 0–100) 30.5 (9.4) 30.3 (10.4)
No. of HIV symptoms (range, 0–12) 5.2 (2.9) 5.1 (3.1)
Depressive severity (range, 0–50) 20.3 (6.9) 19.9 (6.9)
Self-reported antiretroviral adherence (range, 0–100) 85.8 (23.3) 87.2 (22.2)
CD4 count, cells/mm3 607.2 (370.9) 569.0 (354.4)
HIV RNA viral load <50 copies/mL 91 68.9 98 67.6
Abbreviations: HIV, human immunodeficiency virus; SF-12, the Medical Outcomes Study 12-Item Short Form
Health Survey; SLAM DUNC, Strategies to Link Antidepressant and Antiretroviral Management at Duke, University
of Alabama-Birmingham, Northern Outreach Clinic, and the University of North Carolina at Chapel Hill.
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of participants on an antidepressant at entry whose dose or
medication was changed within 30 days, the proportion of
participants not on an antidepressant at entry who received
a prescription within 30 days, and the proportion of all partic-
ipants who received at least 1 antidepressant dose adjustment
within 3 months, all expected to favor the intervention arm.
RESULTS
Overall, 53 attending physicians or mid-level providers
whomanaged patients independently provided informed con-
sent and were randomized, with 28 randomized to a majority-
intervention arm case mix and 25 randomized to majority
usual care (Table 1).The2provider groupswerebalancedwith
respect to site, training, clinical activity, and confidence and
skill in managing antidepressant treatment. Overall, providers
dedicated about two-thirds of their clinical effort to HIV care
and had been caring for HIV patients for a mean of 14 years.
Of the 49 randomized providers with at least 1 enrolled
SLAM DUNC participant, the mean number of participants
per provider, including any patients managed in conjunction
with fellows, was 6.1 (range, 1–18) and 6.3 (range, 1–21) in
the majority-intervention arm and majority-usual care arm
groups, respectively (Table 2). Providers in the majority-
intervention arm group enrolled an average of 4.7 interven-
tion arm and 1.4 usual care arm participants, while providers
in the majority-usual care arm group enrolled an average of
1.5 intervention arm and 4.8 usual care arm participants.
A total of 149 and 155 patients were randomized to the in-
tervention and usual care arms, respectively (Table 3). Partic-
ipants were mostly between 30 and 55 years of age. The
majority were male, black non-Hispanic, and unemployed.
Participants had a mean physical functioning score half a
standard deviation below the US mean of 50 and a mean
mental functioning score 2 standard deviations below the
US mean. No strong evidence of referral bias emerged. There
were small differences between arms in certain demographic
characteristics (intervention arm participants were slightly
younger on average and more likely to be Caucasian), but
the arms were well balanced on baseline physical and mental
health indicators, where referral bias would be expected to be
most evident.
Approximately 45% of participants were taking antide-
pressants prior to study entry, with only a minority taking
moderate or high doses (Table 4). This baseline distribution
was comparable across all groups. In general, for all follow-
up depression treatment indicators, there were pronounced
differences between intervention arm and usual care arm par-
ticipants, but among usual care armparticipants, therewere no
substantive differences between those treated by majority-
usual care versus majority-intervention arm providers, sug-
gesting limited contamination of usual care. For example,
81% of intervention arm participants were taking antidepres-
sants at 3 months compared with 56% of usual care arm partic-
ipants of majority-usual care providers and 59% of usual care
arm participants of majority-intervention providers. Among
intervention arm participants, 41% received at least 1 dose ad-
justment within 3 months compared with 15% of usual care
arm participants of majority-usual care providers and 12% of
usual care arm participants of majority-intervention providers.
In relation to the success of masking, late in the study some
providers did comment informally to study investigators that
they seemed to have gotten all intervention or all usual care pa-
tients, but they did not express any suspicions of imbalance,
Table 4. Assessment of Contaminationa Among HIV Patients With Depression, SLAM DUNC Study, Southern United States, 2010–2014
Depression Treatment
Indicator












(n = 121), % (A)
Majority-Intervention
Arm Providers
(n = 34), % (B)
Antidepressant at baseline
Any 41.2 41.2 0.0 −20.9, 20.9 47.0 5.8 −7.3, 18.9
Moderate or high dose 15.1 17.6 2.5 −14.3, 19.4 16.8 1.7 −6.9, 10.2
Antidepressant at 3 months
Any 55.5 58.8 3.4 −18.4, 25.1 81.2 25.7 14.1, 37.4
Moderate or high dose 22.7 20.6 −2.1 −23.0, 18.8 32.9 10.2 1.9, 18.5
If taking antidepressant at
baseline: Any
adjustment in 30 days?
18.0 7.1 −10.9 −27.3, 5.6 60.0 42.0 27.0, 57.0
If not taking antidepressant
at baseline: Any
antidepressant
prescribed in 30 days?
28.8 26.3 −2.5 −27.7, 22.8 67.1 38.3 20.4, 56.2
All: Any dose adjustment
in 3 months?
14.7 12.1 −2.5 −19.1, 14.0 40.9 26.3 16.1, 36.4
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; SLAM DUNC, Strategies to Link Antidepressant and Antiretroviral
Management at Duke, University of Alabama-Birmingham, Northern Outreach Clinic, and the University of North Carolina at Chapel Hill.
a Comparison of depression treatment indicators between usual care arm participants treated by majority-usual care providers (A), usual care
arm participants treated by majority-intervention arm providers (B), and intervention arm participants (D).
b Regardless of assignment of provider.
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rather attributing it to the “luck of the draw.” At debriefing
after the conclusion of the study, 3 study staff who had been
involved in recruitment commented that they had observed
that certain providers seemed to be getting a lot of interven-
tion arm participants and certain others seemed to be getting a
lot of usual care participants.
DISCUSSION
The SLAM DUNC study used pseudo-cluster randomiza-
tion to balance competing concerns about contamination and
referral bias in a randomized trial of a provider-focused de-
pression management intervention for patients in HIV care.
The study design and masking appear to have been effective
in avoiding referral bias: Had referral bias occurred, differ-
ences would have been expected in the baseline characteris-
tics of participants in the 2 arms, but in fact patients in the
2 arms were comparable on all measured baseline physical
and mental health indicators. There is also no evidence that
majority-usual care arm providers referred with less vigor
than majority-intervention arm providers.
The pseudo-cluster design was selected over patient ran-
domization in order to minimize contamination. The present
design allows a direct assessment of contamination by com-
paring depression treatment indicators between usual care
arm participants managed by majority-usual care arm provid-
ers and usual care arm participants managed by majority-
intervention arm providers, relative to the same indicators
in the intervention arm. Little evidence of contamination
emerged. Usual care arm participants managed by the 2 dif-
ferent types of providers had nearly identical depression treat-
ment indicators, while intervention arm participants had
markedly better indicators. Had substantial contamination
occurred, we would have expected depression treatment indi-
cators for usual care arm participants of majority-intervention
providers to be better (and substantially closer to indicators
for intervention arm participants) than indicators for usual
care arm participants of majority-usual care providers. It
remains possible that some contamination of usual care oc-
curred with both types of providers or that the study was un-
derpowered to identify differences between 2 groups of usual
care participants, but the pronounced differences of both
groups of usual care participants compared with the interven-
tion arm give strongest support to the hypothesis that no or
limited contamination occurred.
The present study masked providers and recruitment staff
to the imbalanced randomization design to provide maximal
protection against referral bias. Although some providers
commented to study investigators that they noticed they had
gotten mostly one or the other type of patient assignment, all
seemed to attribute the imbalance to the luck of the draw
rather than to intentional design. However, masking the im-
balance to study staff may have been more challenging, given
that the same study staff requested randomizations for all
providers at a given site and were therefore more prone to see
patterns in the treatment arm assignments. However, to the
extent that study staff may have suspected imbalance, it does
not appear to have led to referral bias.
At the design stage for this study, the scientific review
panel had strong concerns about the threat of contamination
in a patient-randomized design, and it seemed likely that such
a design would not be funded. At the same time, the investi-
gator team believed that a provider-randomized design would
lead to problematic referral bias. Pseudo-cluster randomization
provided an avenue to address both concerns simultaneously.
Although the weak evidence of contamination suggests after
the fact that the pseudo-cluster design may not have been nec-
essary, there was no firm evidence on which to base such an
argument at the design stage. On the other hand, the fact that
at study exit most providers expressed strong preference for the
intervention over usual care suggests that concern about the
potential for referral bias in a provider-randomized design
was well founded. The use of the pseudo-cluster design pro-
vided a unique opportunity to directly evaluate the extent of
contamination after the fact, providing invaluable information
for future related work. To our knowledge, no other study in
this area has assessed actual contamination in this way.
The SLAMDUNC Study is only the second application of
pseudo-cluster randomization known to the authors, although
suggestions for its usefulness in other settings have been
made (21–23). The experiences presented here are consistent
with reports from the Dutch EASYCare Study, which found
that there was little evidence of suspicion by providers of the
imbalanced randomization probabilities (24). The Dutch
EASYCare investigators also found that providers had a
strong preference for the intervention arm, and that more
than half of the providers said at the end of the study that
they would likely have recruited fewer patients if all their pa-
tients had been assigned to usual care, as would have been the
case in a cluster-randomized trial. This finding is in line with
other reports of slower or biased recruitment among control
clusters in cluster-randomized trials (3, 5–7). Pseudo-cluster
randomization could help to address referral bias even if pro-
viders and staff are not blinded to the imbalanced randomiza-
tion, because each participant has a nonzero probability of
being assigned to either arm.
With increasing emphasis on and funding for implementa-
tion science (25), innovative designs are required that permit
the strongest causal inference and protection against bias
within the constraints of real-world settings. For the present
study, pseudo-cluster randomization appears to have been
effective in preventing referral bias while avoiding contamina-
tion for a real-world study in which both biases were plausible
a priori and would have substantially undermined the random-
ized design’s validity. The design may have applicability in
a range of health service delivery studies that face compet-
ing threats of contamination and referral bias.
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